Analysts Anticipate Evogene Ltd. (EVGN) to Post -$0.18 Earnings Per Share

Equities research analysts forecast that Evogene Ltd. (NASDAQ:EVGN) will post ($0.18) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Evogene’s earnings. Evogene posted earnings per share of ($0.26) in the same quarter last year, which suggests a positive year over year growth rate of 30.8%. The company is expected to issue its next earnings results on Monday, February 26th.

According to Zacks, analysts expect that Evogene will report full-year earnings of ($0.74) per share for the current financial year. For the next year, analysts expect that the firm will report earnings of ($0.44) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Evogene.

Evogene (NASDAQ EVGN) traded up $0.15 during trading on Monday, hitting $3.65. The company’s stock had a trading volume of 2,500 shares, compared to its average volume of 13,163. Evogene has a 1-year low of $3.50 and a 1-year high of $5.84.

An institutional investor recently raised its position in Evogene stock. Vanguard Group Inc. lifted its stake in shares of Evogene Ltd. (NASDAQ:EVGN) by 4.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 436,225 shares of the biotechnology company’s stock after acquiring an additional 17,391 shares during the quarter. Vanguard Group Inc. owned approximately 1.70% of Evogene worth $2,443,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 30.99% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Analysts Anticipate Evogene Ltd. (EVGN) to Post -$0.18 Earnings Per Share” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at

Evogene Company Profile

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.

Get a free copy of the Zacks research report on Evogene (EVGN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Evogene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene Ltd. and related companies with's FREE daily email newsletter.

Leave a Reply